# Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

> **NCT02028780** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo to dose
- **DRUG:** Idarucizumab
- **DRUG:** Placebo to Idarucizumab
- **DRUG:** dabigatran
- **DRUG:** Idarucizumab

## Key facts

- **NCT ID:** NCT02028780
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028780, "Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02028780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*